The deal, offering $2 billion up front and $2 billion in future milestone payments, includes a gene therapy manufacturing facility and a pipeline that includes treatments for Parkinson's and congestive heart failure.
The company acquired 10 AAV-based gene therapies in development for lysosomal storage disorders, including two already in early clinical trials.
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.
AstraZeneca subsidiary and California-based firm to develop AAV-based therapy for chronic lung disease.